Canada: BC Court Of Appeal Dismisses Proposed Consumer Class Action For Invalid Pharmaceutical Patent

Last Updated: December 17 2015
Article by Kiernan A. Murphy

On Dec. 8, 2015, the British Columbia Court of Appeal dismissed a proposed class action by consumers against Pfizer Canada Inc. in connection with Pfizer's now invalid patent which covered its VIAGRA® product.1 The Court of Appeal overturned the lower court's finding that the plaintiff's claim disclosed a cause of action, one of the threshold requirements for certifying a class action. Britton Low, the proposed representative plaintiff, alleged that Pfizer unlawfully abused the patent system, and as a result, was able to overcharge purchasers of VIAGRA. The lower court found that it was plain and obvious that Mr. Low's claim in waiver of tort could not succeed, but allowed his claims for interference with economic relations and unjust enrichment to go forward. However, in a unanimous decision, the Court of Appeal found that those claims also could not succeed.

In particular, the Court of Appeal held that the Patent Regulatory Regime2 constitutes a complete code. Even though this regime includes no remedy for consumers for conduct alleged to have breached that regime, the Court held that:

...the completeness of the Patent Regulatory Regime forecloses parallel civil actions by consumers that are rooted in a breach of the Patent Act... [T]here is nothing in the legislation comprising the Patent Regulatory Regime ... that evinces an intention to allow consumers to make such claims.


Pfizer obtained a patent on the use of several compounds, including sildenafil (the medicinal ingredient in VIAGRA), in the treatment of erectile dysfunction. In 2006, a generic manufacturer sought regulatory approval to market a copycat version of VIAGRA, and was thus required to address that patent pursuant to the Patented Medicines (Notice of Compliance) Regulations (the "NOC Regulations"). The generic asserted that Pfizer's patent was invalid. Pfizer commenced a prohibition proceeding under those regulations, triggering an automatic stay of that generic's regulatory approval. The Federal Court granted prohibition, finding the generic's allegations to be unjustified, and the Court of Appeal upheld that order. However, the Supreme Court of Canada then found one of the allegations of invalidity to be justified and dismissed the prohibition application, allowing the generic to enter the market.

Patent Regulatory Regime is a Complete Code

The Court of Appeal held that several decisions of the Federal Court of Appeal support the notion that the Patent Regulatory Regime is a complete code as between brands and generics. For example, it highlighted a decision finding a claim by a generic manufacturer beyond the Patent Regulatory Regime could not possibly succeed because the allegedly wrongful acts were the same as those underlying liability under that regime.3 The Court of Appeal also referred to the Ontario Court of Appeal's finding4 that the Patent Regulatory Regime does not leave room for any stand-alone equitable remedies.

The Court of Appeal noted that comprehensive statutory schemes may preclude common law rights, including unjust enrichment. It clarified that the Patent Regulatory Regime does not confer any direct benefit or protection on consumers and thus the absence of an enforcement mechanism in this regime cannot imply a common law private cause of action by a consumer.

As quoted above, the Court of Appeal concluded that nothing in the Patent Regulatory Regime conveys an intention to permit parallel civil actions by consumers that are rooted in a breach of the Patent Act. Indeed, it noted that it would make no sense to allow consumers to claim disgorgement of profits from brands when generics are precluded from doing the same based on identical allegedly wrongful acts.

In any event, the Court of Appeal noted that there was evidence that Parliament had in fact considered consumer interests and chose to create, for example, the Patented Medicines Prices Review Board to reduce prices deemed excessive.

No Cause of Action for Unjust Enrichment or Interference with Economic Relations

The Court of Appeal also held that Pfizer could not be liable for conduct grounding Mr. Low's claim for interference with economic relations because it has no corresponding liability to generics (outside of the NOC Regulations) for the same conduct. This tort creates a "parasitic" liability as it requires a distinct unlawful act (or actionable civil wrong of some kind). A breach of statute (such as the Patent Act) must therefore be actionable outside the context of the statute itself. Mr. Low had alleged that Pfizer's acts were actionable by third party generic drug manufacturers who were kept off the market. The Court of Appeal however noted that generics could only claim their own losses pursuant to the NOC Regulations. As such, it held that, if generics have no cause of action against brands beyond those regulations, then the entirely parasitic tort of unlawful interference with economic relations could not succeed.

The Court of Appeal confirmed that complete statutory codes, such as the Patent Regulatory Regime, exclude equitable claims in unjust enrichment and thus Mr. Low had no claim in this regard. It added that the lower court ought to have found that this claim had no prospect of success in any event, having held that Pfizer's contracts with its direct purchasers (e.g., distributors or pharmacies) constituted a juristic reason for any benefits obtained by Pfizer. The Court of Appeal held that a single juristic reason is enough to defeat an unjust enrichment claim.


The Court of Appeal's finding that none of the proposed claims met the very low threshold for establishing that the proposed class action discloses a cause of action during the certification process should provide some comfort to brands seeking to exercise patent rights which could subsequently be found invalid. In addition, its conclusion in the context of consumer claims that the Patent Regulatory Regime is a complete code clarifies the scope of, and available rights under, that regime. That finding, in line with recent jurisprudence involving generics, further confines the redress generics may seek for being kept off the market by application of the NOC Regulations to that expressly set out in those regulations.


1. Low v Pfizer Canada Inc.,2015 BCCA 506

2. The Court of Appeal referred collectively to the Patent Act, R.S.C. 1985, c. P-4, the Food and Drugs Act, R.S.C. 1985, c. F-27, the Food and Drug Regulations, C.R.C., c. 870, Part C, Division 8, C.08.004, and the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 as the "Patent Regulatory Regime".

3. Apotex v Eli Lilly, 2011 FCA 358

4. Apotex Inc v Abbot Laboratories Ltd, 2013 ONSC 356, aff'd 2013 ONCA 555

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
Blake, Cassels & Graydon LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
Blake, Cassels & Graydon LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions